Arbutus Biopharma (ABUS) Change in Acquisitions & Divestments (2018 - 2025)
Arbutus Biopharma (ABUS) has disclosed Change in Acquisitions & Divestments for 9 consecutive years, with $23.8 million as the latest value for Q4 2025.
- Quarterly Change in Acquisitions & Divestments fell 57.96% to $23.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $155.3 million through Dec 2025, down 5.69% year-over-year, with the annual reading at $155.3 million for FY2025, 5.69% down from the prior year.
- Change in Acquisitions & Divestments hit $23.8 million in Q4 2025 for Arbutus Biopharma, down from $41.3 million in the prior quarter.
- In the past five years, Change in Acquisitions & Divestments ranged from a high of $56.7 million in Q4 2024 to a low of $2.0 million in Q1 2022.
- Historically, Change in Acquisitions & Divestments has averaged $28.9 million across 5 years, with a median of $27.2 million in 2022.
- Biggest five-year swings in Change in Acquisitions & Divestments: plummeted 90.17% in 2022 and later skyrocketed 1750.0% in 2023.
- Year by year, Change in Acquisitions & Divestments stood at $20.0 million in 2021, then increased by 30.0% to $26.0 million in 2022, then soared by 77.86% to $46.2 million in 2023, then rose by 22.58% to $56.7 million in 2024, then crashed by 57.96% to $23.8 million in 2025.
- Business Quant data shows Change in Acquisitions & Divestments for ABUS at $23.8 million in Q4 2025, $41.3 million in Q3 2025, and $44.1 million in Q2 2025.